Tag: Sarvesh Mutha
“The global needle-free injector market is projected to reach $27.65 billion...
Sarvesh Mutha, Managing Director, IntegriMedical shares his insights on the company’s major achievements, latest offerings and way forward
BioVoice eMagazine July-August 2025 | Issue 7 | Volume 6
The Cover Story explores renewed fears around COVID-19 vaccination. This edition also features expert insights from Enbasekar D, Co-Founder & CTO of MediBuddy, along with interviews of Nandakumar Kalathil (Agilent Technologies India), Malti Sachdev (Siemens Healthineers), and Sarvesh Mutha (IntegriMedical)
Serum Institute to acquire 20% stake in IntegriMedical, India’s first needle-free...
The investment by SII in IntegriMedical is expected to accelerate the development and commercialization of the N-FIS technology, making it more widely accessible to patients in India and worldwide